Pfizer’s ABRYSVO RSV vaccine approved by FDA for broader adult use
The vaccine is now approved for adults aged 18 to 59 at higher risk of RSV-related respiratory illness, expanding its prior…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.